Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to provide individual exposure measures for input in...

Descripción completa

Detalles Bibliográficos
Autores principales: Solms, Alexander, Frede, Matthias, Berkowitz, Scott D., Hermanowski‐Vosatka, Anne, Kubitza, Dagmar, Mueck, Wolfgang, Spiro, Theodore E., Willmann, Stefan, Yan, Xiaoyu, Zhang, Liping, Garmann, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875705/
https://www.ncbi.nlm.nih.gov/pubmed/31276324
http://dx.doi.org/10.1002/psp4.12444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875705/
https://www.ncbi.nlm.nih.gov/pubmed/31276324
http://dx.doi.org/10.1002/psp4.12444

Ejemplares similares